Clinical Trial Update: Korean Post-marketing Surveillance for Onglyza®

View source ↗

Summary

Completed Korean post-marketing surveillance study evaluating Onglyza (saxagliptin) for type 2 diabetes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Onglyza (Saxagliptin)

Snippet

Sponsor: AstraZeneca | Conditions: Diabetes Mellitus, Type 2 | Status: COMPLETED